These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 32010130)

  • 21. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer cells in the treatment of high-risk acute leukaemia.
    Locatelli F; Moretta F; Brescia L; Merli P
    Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NK cell-based therapeutics for lung cancer.
    Pockley AG; Vaupel P; Multhoff G
    Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
    [No Abstract]   [Full Text] [Related]  

  • 24. Tricking the balance: NK cells in anti-cancer immunity.
    Pahl J; Cerwenka A
    Immunobiology; 2017 Jan; 222(1):11-20. PubMed ID: 26264743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Harnessing NK Cells for Cancer Treatment.
    Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
    Front Immunol; 2019; 10():2836. PubMed ID: 31867006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
    Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
    Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Risk Leukemia: Past, Present, and Future Role of NK Cells.
    Mavers M; Bertaina A
    J Immunol Res; 2018; 2018():1586905. PubMed ID: 29850617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells.
    Stojanovic A; Fiegler N; Brunner-Weinzierl M; Cerwenka A
    J Immunol; 2014 May; 192(9):4184-91. PubMed ID: 24688023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
    Kamiya T; Seow SV; Wong D; Robinson M; Campana D
    J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of natural killer cells in cancer therapy and transplantation.
    Knorr DA; Bachanova V; Verneris MR; Miller JS
    Semin Immunol; 2014 Apr; 26(2):161-72. PubMed ID: 24618042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
    Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
    J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.
    Malmberg KJ; Sohlberg E; Goodridge JP; Ljunggren HG
    Immunogenetics; 2017 Aug; 69(8-9):547-556. PubMed ID: 28699110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NK cell killer Ig-like receptor repertoire acquisition and maturation are strongly modulated by HLA class I molecules.
    Sleiman M; Brons NH; Kaoma T; Dogu F; Villa-Forte A; Lenoble P; Hentges F; Kotsch K; Gadola SD; Vilches C; Zimmer J
    J Immunol; 2014 Mar; 192(6):2602-10. PubMed ID: 24554773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
    Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
    Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on the current revolution in cancer immunotherapy.
    Renrick AN; Dunbar ZT; Shanker A
    Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010
    [No Abstract]   [Full Text] [Related]  

  • 40. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.